Abstract
Several pharmacophore models were previously formulated to account for the actions of nicotinic acetylcholinergic (nACh) agents. Most of these models were developed without express consideration of specific radioligand binding data because such data were not available at the time the models were described. In this review, the ability of these models to account for the binding of nicotinic agents at α4β2 nACh receptors (or rat brain receptors for which α4β2 receptors are the major component) is assessed. It seems that none of the early models can adequately explain the binding of these agents as a group. Furthermore, different series of nicotinic agents behave differently depending upon the nature of terminal amine substituents and the spacer that separates the amine from the pyridine ring. A region of bulk tolerance has been identified that accommodates substituents on some nicotinic ligands, but not the same substituents at seemingly corresponding locations of others. The concept of multiple modes of binding has been previously raised and, clearly, cannot yet be discarded. Nevertheless, new vector models seemingly provide a better picture of nACh receptor binding and account for many of the shortcomings associated with the earlier models.
Keywords: Nicotinic Acetylcholine, pyridine ring
Current Topics in Medicinal Chemistry
Title: Musings on α4β2 Nicotinic Acetylcholine (nACh) Receptor Pharmacophore Models
Volume: 4 Issue: 6
Author(s): Richard A. Glennon, Malgorzata Dukat and Liang Liao
Affiliation:
Keywords: Nicotinic Acetylcholine, pyridine ring
Abstract: Several pharmacophore models were previously formulated to account for the actions of nicotinic acetylcholinergic (nACh) agents. Most of these models were developed without express consideration of specific radioligand binding data because such data were not available at the time the models were described. In this review, the ability of these models to account for the binding of nicotinic agents at α4β2 nACh receptors (or rat brain receptors for which α4β2 receptors are the major component) is assessed. It seems that none of the early models can adequately explain the binding of these agents as a group. Furthermore, different series of nicotinic agents behave differently depending upon the nature of terminal amine substituents and the spacer that separates the amine from the pyridine ring. A region of bulk tolerance has been identified that accommodates substituents on some nicotinic ligands, but not the same substituents at seemingly corresponding locations of others. The concept of multiple modes of binding has been previously raised and, clearly, cannot yet be discarded. Nevertheless, new vector models seemingly provide a better picture of nACh receptor binding and account for many of the shortcomings associated with the earlier models.
Export Options
About this article
Cite this article as:
Glennon A. Richard, Dukat Malgorzata and Liao Liang, Musings on α4β2 Nicotinic Acetylcholine (nACh) Receptor Pharmacophore Models, Current Topics in Medicinal Chemistry 2004; 4 (6) . https://dx.doi.org/10.2174/1568026043451122
DOI https://dx.doi.org/10.2174/1568026043451122 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epidemiology, Evolution, Transmission, and Therapeutics of COVID-19 Outbreak: An Update on the Status
Coronaviruses Progress in Computational Approach to Drug Development Against SARS
Current Medicinal Chemistry Gallium Components-Based Drug Delivery: A Potential Treatment for COVID-19
Infectious Disorders - Drug Targets Polynuclear Ruthenium, Osmium and Gold Complexes. The Quest for Innovative Anticancer Chemotherapeutics
Current Topics in Medicinal Chemistry 1,3,4-Oxadiazole Derivatives as Potential Biological Agents
Mini-Reviews in Medicinal Chemistry ACEi/ ARB and Deaths of COVID-19 Patients
Current Hypertension Reviews Editorial [ Infectious Diseases: What is in our future? ]
Infectious Disorders - Drug Targets SARS-CoV-2 Transmission Among Healthcare Workers in Iran: An Urgent Need for Early Identification and Management
Infectious Disorders - Drug Targets Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Update on the Medical Treatment of Allergic Rhinitis
Inflammation & Allergy - Drug Targets (Discontinued) MicroRNAs in Prostate Cancer Following Radiotherapy: Towards Predicting Response to Radiation Treatment
Current Medicinal Chemistry Semicarbazone Analogs as Anticonvulsant Agents: A Review
Central Nervous System Agents in Medicinal Chemistry Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Computational Insights into Binding of Bisphosphates to Farnesyl Pyrophosphate Synthase
Current Medicinal Chemistry Natural Compounds Containing a Condensed Cyclopropane Ring. Natural and Synthetic Aspects
Current Organic Chemistry Design, Synthesis and Biopharmacological Profile Evaluation of New 2-((4- Chlorophenoxy)Methyl)-N-(Arylcarbamothioyl)Benzamides with Broad Spectrum Antifungal Activity
Current Organic Chemistry Recent Techniques Used in Reproductive Medicine: Outcomes for Gametes Manipulation
Current Women`s Health Reviews miRNAs in SARS-CoV 2: A Spoke in the Wheel of Pathogenesis
Current Pharmaceutical Design The Bananins: New Anticorona-RNA-Viral Agents with Unique Structural Signature
Anti-Infective Agents in Medicinal Chemistry Therapeutic Implications of Immunoparalysis in Critically Ill Patients
Inflammation & Allergy - Drug Targets (Discontinued)